Page last updated: 2024-11-12

gala peptide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

GALA peptide: synthetic 30 amino acid peptide; its association with membrane vesicles has been studied; amino acid sequence given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID16131086
MeSH IDM0183637

Synonyms (6)

Synonym
l-alanine, l-tryptophyl-l-alpha-glutamyl-l-alanyl-l-alanyl-l-leucyl-l-alanyl-l-alpha-glutamyl-l-alanyl-l-leucyl-l-alanyl-l-alpha-glutamyl-l-alanyl-l-leucyl-l-alanyl-l-alpha-glutamyl-l-histidyl-l-leucyl-l-alanyl-l-alpha-glutamyl-l-alanyl-l-leucyl-l-alanyl-
l-tryptophyl-l-alpha-glutamyl-l-alanyl-l-alanyl-l-leucyl-l-alanyl-l-alpha-glutamyl-l-alanyl-l-leucyl-l-alanyl-l-alpha-glutamyl-l-alanyl-l-leucyl-l-alanyl-l-alpha-glutamyl-l-histidyl-l-leucyl-l-alanyl-l-alpha-glutamyl-l-alanyl-l-leucyl-l-alanyl-l-alpha-glu
gala peptide
glutamic acid-alanine-leucine-alanine repeat peptide
107658-43-5
cid 16131086

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" In combination with cationic liposomes, Lipofectamine 2000 (LF2000), the feasibility of this approach for the cytosolic targeting of proteins and nanoparticles was exemplified through the delivery of avidin (68 kDa) and streptavidin-coated quantum dots (15-20 nm) in serum-containing medium."( Cytosolic targeting of macromolecules using a pH-dependent fusogenic peptide in combination with cationic liposomes.
Futaki, S; Giralt, E; Imanishi, M; Kawabata, N; Kobayashi, S; Nakase, I; Pujals, S; Yu, HH, 2009
)
0.35

Dosage Studied

ExcerptRelevanceReference
" Successful reduction in the liposomal dosage was attained by employing GALA while maintaining a high transfection efficiency."( Unique features of a pH-sensitive fusogenic peptide that improves the transfection efficiency of cationic liposomes.
Futaki, S; Harashima, H; Kogure, K; Masui, Y; Nakamura, T; Nakase, I; Sugiura, Y, 2005
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (60)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (5.00)18.7374
1990's8 (13.33)18.2507
2000's17 (28.33)29.6817
2010's27 (45.00)24.3611
2020's5 (8.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.60

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.60 (24.57)
Research Supply Index4.13 (2.92)
Research Growth Index5.05 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.60)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (6.56%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other57 (93.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]